Literature DB >> 9364698

Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.

K Kurtenbach1, A Dizij, P Voet, P Hauser, M M Simon.   

Abstract

As observed in humans, immune responses in naturally infected reservoir hosts of Borrelia burgdorferi sensu lato rarely target the outer surface proteins (Osp) A and B of Lyme disease spirochaetes. The absence of protective immunity in such hosts following tick-borne infection allows them to play an effective role in the maintenance of Lyme borreliosis in nature. Therefore, the question was addressed whether one of the most prominent natural reservoir host species of B. burgdorferi s.l. in Europe, the yellow-necked mouse (Apodemus flavicollis), may lack the ability to elicit transmission-blocking antibodies to Lyme borreliosis spirochaetes. Yellow-necked mice were immunized with a recombinant lipidated OspA from B. burgdorferi sensu stricto or with high numbers of UV-irradiated whole spirochaetes. All immunized mice, but not untreated controls, developed polyclonal humoral immune responses to OspA (31 kDa). Serum antibodies of animals vaccinated with the recombinant OspA contained high levels of antibody to an epitope of OspA, defined by the monoclonal antibody LA-2, whereas only low levels of LA-2 equivalent antibodies could be detected in sera from animals immunized with killed spirochaetes. Ixodes ricinus ticks infected with B. burgdorferi s.s. lost their spirochaete load after feeding on animals with high levels of LA-2 equivalent antibody; ticks feeding on animals which had only low or undetectable serum levels of LA-2 equivalent antibodies retained their spirochaete infection. Furthermore, animals with high levels of LA-2 equivalent antibody were protected against spirochaete infection. Our study shows that natural mouse reservoir hosts are highly competent to generate transmission-blocking antibodies after vaccination with a lipidated recombinant OspA and indicates that antibodies to the LA-2 epitope play a key role in the destruction of B. burgdorferi s.s. within feeding Ixodes ricinus ticks.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364698     DOI: 10.1016/s0264-410x(97)00086-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Serum complement sensitivity as a key factor in Lyme disease ecology.

Authors:  K Kurtenbach; H S Sewell; N H Ogden; S E Randolph; P A Nuttall
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

2.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.

Authors:  Luciana Meirelles Richer; Miguel Aroso; Tania Contente-Cuomo; Larisa Ivanova; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

Review 4.  Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.

Authors:  Wen-Hsiang Chen; Ulrich Strych; Maria Elena Bottazzi; Yi-Pin Lin
Journal:  Expert Rev Vaccines       Date:  2022-07-22       Impact factor: 5.683

5.  Non-anticoagulant Heparin as a Pre-exposure Prophylaxis Prevents Lyme Disease Infection.

Authors:  Yi-Pin Lin; Yanlei Yu; Ashley L Marcinkiewicz; Patricia Lederman; Thomas M Hart; Fuming Zhang; Robert J Linhardt
Journal:  ACS Infect Dis       Date:  2020-01-30       Impact factor: 5.084

6.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

7.  Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Authors:  Michael G Schwendinger; Maria O'Rourke; Andreas Traweger; Helga Savidis-Dacho; Andreas Pilz; Daniel Portsmouth; Ian Livey; P Noel Barrett; Brian A Crowe
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.